Marelius® Biopharma Group Ltd
Biopharma | Regulatory | Clinical Services
Marelius® Biopharma Group Ltd is a specialist biopharmaceutical and life-sciences organisation providing regulatory, clinical, and strategic support to biotechnology and therapeutics programmes operating in highly regulated environments.
Comprehensive guidance across regulatory strategy, clinical development, and international execution, helping programmes progress efficiently from early development.
Evidence-based strategies and cross-border operational capabilities that support market-facing stages across multiple international jurisdictions.
Collaborating closely with sponsors, investigators, and regulatory authorities to combine scientific rigor with commercial insight.
Deep experience across major regulatory frameworks
Specialised contract manufacturing support for the biopharmaceutical industry.
Elevating standards through comprehensive education and hands-on GMP workshops.
Navigating regulatory ambiguity in 'High-Trust' nodes.
Moving beyond the fee-for-service model to align with long-term outcomes.
Marelius® Biopharma Group Ltd continues to support biotechnology and therapeutics programmes through regulatory strategy, clinical development support, and international execution. The company operates as part of the Marelius group, which includes Marelius Inc. (OTC: MBPG), and works with sponsors, investigators, and strategic partners across regulated healthcare environments.
Dr Haque leads Marelius® Biopharma Group Ltd with over 35 years of international experience in healthcare, biotechnology, and life sciences. His career includes senior executive roles at Stryker Corporation (NYSE: SYK) and Wright Medical Group (NASDAQ: WMGI), and he currently serves as CEO of Marelius Inc. (OTCID: MBPG).
Dr Haque's leadership combines clinical insight with deep regulatory and commercial expertise, managing teams and consultants to support clients through complex development pathways across FDA, EMA, and MHRA jurisdictions.
View Profile